ONC · BeOne Medicines Ltd. · Earnings Call Transcripts & Audio
$365.94
+0.67 (+0.18%)
At close · Sep 30
Return incl. dividend (before tax)
Market Cap
$40.82B
Shares
113.12M
Volume · Sep 30
329.05K
Avg daily vol (3M)
388K
BeOne Medicines Ltd. Earnings Call Transcripts
Quarterly earnings calls for BeOne Medicines Ltd. (ONC), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲74.3%
$595.26M
−$381.14M
'23 Q2
23-08-02
▲28.2%
$1.00B
−$121.35M
'24 Q3
24-12-16
▲77.8%
$1.13B
−$151.88M
'24 Q4
25-02-27
▲48.6%
$1.12B
$1.27M
'25 Q1
25-05-07
▲41.6%
$1.32B
$94.32M
'25 Q2
25-08-06
▲41%
$1.41B
$124.84M
'25 Q3
25-11-06
▲32.8%
$1.50B
$66.50M
'25 Q4
26-02-26
▲35.5%
$1.51B
$227.36M
'26 Q1
26-05-06
LATEST
▲29.6%
$1.71B
$237.01M
'26 Q2
26-08-05
Conference
Investor event
2026-09-14
BeOne Medicines Ltd. (ONC) September 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-08-05
BeOne Medicines Ltd. (ONC) Q2 2026 Earnings Call
Revenue
$1.71B
▲ 29.6% YoY Diluted EPS
$0.16
▲ 166.7% YoY Gross margin
89.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-08
BeOne Medicines Ltd. (ONC) June 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-06-08
BeOne Medicines Ltd. (ONC) June 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-06
BeOne Medicines Ltd. (ONC) Q1 2026 Earnings Call
Revenue
$1.51B
▲ 35.5% YoY Diluted EPS
$0.15
Gross margin
89.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-26
BeOne Medicines Ltd. (ONC) Q4 2025 Earnings Call Transcript
Confident tone
BRUKINSA franchise leadership in CLL
Fixed-duration vs continuous treatment dynamics
Pipeline progress and R&D momentum
Revenue
$1.50B*
▲ 32.8% YoY Gross margin
90.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-06
BeOne Medicines Ltd. (ONC) Q3 2025 Earnings Call Transcript
Confident tone
Sonro (BCL2 inhibitor) and zanu+sonro combination
BRUKINSA commercial momentum and global leadership
ASH 2025 data presentations and scientific leadership
Revenue
$1.41B
▲ 41% YoY Diluted EPS
$0.08
Gross margin
86.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-06
BeOne Medicines Ltd. (ONC) Q2 2025 Earnings Call Transcript
Confident tone
BRUKINSA commercial leadership
CLL franchise and ALPINE data
Financial results and cash flow
Revenue
$1.32B
▲ 41.6% YoY Diluted EPS
$0.06
Gross margin
87.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-07
BeOne Medicines Ltd. (ONC) Q1 2025 Earnings Call Transcript
Confident tone
Global commercial expansion
BRUKINSA commercial leadership
Pipeline progression
Revenue
$1.12B
▲ 48.6% YoY Diluted EPS
$0.00
Gross margin
85.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-27
BeOne Medicines Ltd. (ONC) Q4 2024 Earnings Call
Revenue
$1.13B*
▲ 77.8% YoY Gross margin
85.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-12-16
BeOne Medicines Ltd. (ONC) Q3 2024 Earnings Call
Revenue
$1.00B
▲ 28.2% YoY Diluted EPS
$-0.09
▼ 160% YoY Gross margin
83.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-02
BeOne Medicines Ltd. (ONC) Q2 2023 Earnings Call
Revenue
$595.26M
▲ 74.3% YoY Diluted EPS
$-0.28
Gross margin
83.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Showing 1–12 of 12 earnings calls
Key facts
CIK
1651308
CUSIP
07725L102
13F (30d)
10 filings
8 filers
Visit website
Investor relations